Nadir Mahmood, Ph.D., is a distinguished leader in the biotechnology industry, currently serving as the President of NKARTA INC. Dr. Mahmood brings a wealth of experience in drug development, with a particular focus on oncology and immunology. Before joining NKARTA INC, he held significant roles at several prominent biotech firms, including Amgen and Genentech, where he was instrumental in advancing multiple therapeutic candidates from early-stage research through to clinical development and eventual market approval. His strategic vision and deep scientific knowledge have made him a pivotal figure in the development of innovative cancer treatments. At NKARTA INC, Dr. Mahmood oversees the company's mission to harness the power of natural killer (NK) cells to develop transformative therapies for cancer and other serious diseases. Under his leadership, NKARTA has made significant strides in its clinical pipeline, advancing several NK cell therapies into clinical trials. His role involves not only guiding the scientific direction of the company but also fostering partnerships and collaborations that enhance NKARTA's research capabilities and market reach. Dr. Mahmood's commitment to advancing patient care through cutting-edge science has been a driving force behind NKARTA's success and growth. Dr. Mahmood's achievements extend beyond his corporate roles; he is also an active member of the scientific community, frequently contributing to academic journals and speaking at industry conferences. His work has been recognized with numerous awards and accolades, reflecting his impact on the field of oncology and immunotherapy. As President of NKARTA INC, Nadir Mahmood continues to lead with a focus on innovation, collaboration, and a steadfast dedication to improving patient outcomes.